BofA warns Fed risks policy mistake with early rate cuts
SEATTLE—Johan M. Spoor, the Chief Executive Officer of Perspective Therapeutics, Inc. (NASDAQ:CATX), recently purchased shares of the company’s common stock valued at approximately $59,672. The transactions, which took place on March 28, involved acquiring a total of 26,676 shares at prices ranging from $2.2125 to $2.2421 per share. According to InvestingPro data, these purchases come as the stock trades near its 52-week low of $1.90, down significantly from its high of $19.05.
The purchases were executed in multiple transactions, with 22,026 shares acquired directly by Spoor and an additional 4,650 shares purchased by a family member. Following these acquisitions, Spoor’s direct holdings increased to 59,383 shares. The transactions were disclosed in a filing with the Securities and Exchange Commission, reflecting the CEO’s continued investment in the company. InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 12.68 and more cash than debt on its balance sheet.
In addition to the recent purchases, Spoor holds indirect ownership of additional shares through family accounts, including those held by his spouse and children. These holdings are part of a broader portfolio that includes shares held in Individual Retirement Accounts (IRAs) and Uniform Transfers to Minors Act accounts.
The transactions highlight Spoor’s confidence in the future of Perspective Therapeutics, a company focused on surgical and medical instruments and apparatus. Investors often watch insider transactions closely as they can provide insight into the company’s prospects.
In other recent news, Perspective Therapeutics Inc has been the focus of several financial analysts following updates on its therapeutic programs and financial status. Oppenheimer maintained its Outperform rating on the company, keeping a price target of $16.00, citing the expansion of the VMT-α-NET trial and a strong cash balance of $227 million that is expected to support operations until late 2026. This financial stability supports the company’s ongoing research without immediate financial pressure. Scotiabank (TSX:BNS) also initiated coverage with a Sector Outperform rating and set a price target of $15.00, highlighting the company’s potential in its melanoma, FAP-alpha, and pre-targeting platform programs. The bank noted that the recent dip in stock price might be an attractive entry point for investors.
Additionally, Lucid (NASDAQ:LCID) Capital Markets raised its price target for Perspective Therapeutics to $20.00 from $15.00, maintaining a Buy rating. This adjustment followed the presentation of new data for the VMT-α-NET (Pb-212 radioligand) at the ASCO GI 2025 conference, which suggested the drug could be best-in-class. Lucid Capital Markets indicated that these findings have mitigated some prior concerns and reinforced confidence in the drug’s safety and efficacy. The firm emphasized the stock as a buying opportunity, given the potential for further positive data. These developments underscore the growing interest and confidence in Perspective Therapeutics’ pipeline and financial health among analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.